AMANDA MURPHY
Associate Director, Investor Relations & Public Relations, Aegerion Pharmaceuticals
Email: amanda.murphy@aegerion.com
Phone: 857-242-5024
Aegerion strengthens balance sheet and liquidity, positioning company for ongoing capital structure review
Novelion reports 2017 total net revenues of $138.4 million, in line with previously stated guidance
Plans underway to address capital structure and advance metreleptin development program
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases
